Printer Friendly

Research and Markets: Crohn's Disease (Event Driven).

DUBLIN -- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Crohn's Disease (Event Driven)" to their offering.

Treatment options for Crohn's disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis factor-alpha (TNF-a) inhibitors. Despite the clinical and commercial success of the TNF-a inhibitors, opportunity remains for agents that can safely and effectively induce and maintain remission in a significant number of patients with moderate to severe CD.

Emerging therapies with different mechanisms of actionincluding the interleukin (IL)-12/IL-23 inhibitor ustekinumab (Janssen Biotech/Janssen Cilag's Stelara), the cell adhesion molecule (CAM) inhibitor vedolizumab (Millennium Pharmaceuticals), and the chemokine receptor inhibitor GSK-1605786 (formerly Traficet-EN or CCX-282B; GlaxoSmithKline/ChemoCentryx)are in clinical development for CD.

However, interviewed thought leaders do not expect these drugs to displace the TNF-a inhibitors as the dominant drug class for moderate to severe CD. The estimated high pricing of ustekinumab, which is already marketed for psoriasis, and concerns about the risk of progressive multifocal leukoencephalopathy (PML) for vedolizumab will have implications for the CD market.

Key Topics Covered:

- Executive Summary

- What are the key parameters of the Crohn's disease market?

- What factors are driving the market for Crohn's disease therapies?

- What factors are constraining the market for Crohn's disease therapies?

- What are the drug development activities of note in Crohn's disease?

- What do the experts say?

- What key challenges and opportunities remain?

- 1 Etiology and Pathophysiology

- 2 Epidemiology and Patient Populations

- 3 Current Therapies and Medical Practice

- 4 Unmet Needs

- 5 Emerging Therapies

- 6 Market Outlook

- Appendix A BibliographyCrohn's Disease

- Appendix B Market Forecast Methodology

- Appendix C Experts InterviewedCrohn's Disease

- Appendix D Supplemental Epidemiology BibliographyCrohn's Disease

- Tables and Figures

For more information visit

Source: Decision Resources, Inc
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 20, 2012
Previous Article:Research and Markets: Osteoporosis (Event Driven).
Next Article:Research and Markets: Male Cancer - Pipeline Review, H2 2012.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters